Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;13(2):125-30.
doi: 10.1007/s11904-016-0309-9.

Cascade of Refusal-What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa?

Ingrid T Katz  1   2   3 , David R Bangsberg  4   5
Affiliations
Review

Cascade of Refusal-What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa?

Ingrid T Katz et al. Curr HIV/AIDS Rep. 2016 Apr.

Abstract

Recent recommendations by the World Health Organization support treatment for all people living with HIV (PLWH) globally to be initiated at the point of testing. While there has been marked success in efforts to identify and expand treatment for PLWH throughout sub-Saharan Africa, the goal of universal treatment may prove challenging to achieve. The pre-ART phase of the care cascade from HIV testing to HIV treatment initiation includes several social and structural barriers. One such barrier is antiretroviral therapy (ART) treatment refusal, a phenomenon in which HIV-infected individuals choose not to start treatment upon learning their ART eligibility. Our goal is to provide further understanding of why treatment-eligible adults may choose to present for HIV testing but not initiate ART when indicated. In this article, we will discuss factors driving pre-ART loss and present a framework for understanding the impact of decision-making on early losses in the care cascade, with a focus on ART refusal.

Keywords: ART refusal; Antiretroviral medications; Global epidemic; HIV prevention; HIV/AIDS; Point of testing; Review; Science of prevention; Treatment refusal.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Four categories of ART initiation
See this image and copyright information in PMC

References

    1. Joint United Nations Programme on HIV/AIDS (UNICEF) How AIDS changed everything—MDG 6: 15 years, 15 lessons of hope from the AIDS response. Geneva, Switzerland: 2015. [Accessed 22 August 2015]. http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf.
    1. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Eng J Med. 2015 doi: 10.1056/NEJMoa1506816. A trial of over 4000 patients in 35 countries, showed that the risk of death, a serious AIDS-related event, or a serious non–AIDS-related event was 57% lower among those treated early than among those treated when the CD4+ cell count decreased to 350 cells per cubic millimeter. INSIGHTand TEMPRANO confirm previous observational studies and add important new evidence that advances our knowledge of the risks and benefits of early ART in patients with CD4+ cell counts of more than 500 cells per cubic millimeter. - DOI - PMC - PubMed
    1. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Eng J Med. 2015 doi: 10.1056/NEJMoa1507198. This study involved over 2000 patients in the Ivory Coast, and showed that early ART initiation was associated with a 44% lower risk of death or severe HIV-related illness than was ART initiated according to prevailing World Health Organization criteria. - DOI - PubMed
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: 2015. Available from: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?.... Accessed: Accessed. - PubMed

Publication types

Substances

LinkOut - more resources